Compare AMR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | NVAX |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | AMR | NVAX |
|---|---|---|
| Price | $183.27 | $6.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $168.00 | $10.78 |
| AVG Volume (30 Days) | 248.7K | ★ 3.5M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $2,226,356,000.00 | $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | ★ N/A | $3.17 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $97.41 | $5.01 |
| 52 Week High | $233.20 | $11.55 |
| Indicator | AMR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 39.20 |
| Support Level | $170.13 | $6.57 |
| Resistance Level | $185.77 | $6.84 |
| Average True Range (ATR) | 8.79 | 0.22 |
| MACD | 2.35 | 0.05 |
| Stochastic Oscillator | 79.71 | 28.00 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.